Erlotinib plus bevacizumab combination studies
Erlotinib plus bevacizumab is a clinical guideline-recommended first-line treatment option for EGFR Mut+ NSCLC.1
Bevacizumab is an anti-VEGF monoclonal antibody that inhibits tumour growth by inhibiting new and recurrent tumour vessel growth.2
Bevacizumab also reduces tumour size by regressing existing tumour vasculature.2-4
Please click below for more information on the key clinical trials that demonstrate
erlotinib plus bevacizumab’s favourable efficacy and safety profile in the first-line treatment of EGFR Mut+ NSCLC.
Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed